• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

ACKR1 variant increases risk of azathioprine-related hematopoietic toxicity

byDavid XiangandKiera Liblik
June 30, 2022
in Chronic Disease, Hematology, Rheumatology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients with the ACKR1 variant (CC genotype) had an elevated risk of azathioprine discontinuation attributed to hematopoietic toxicity.

2. The CC genotype group remained at elevated risk after adjustment for sociodemographic characteristics, including race.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Azathioprine is a thiopurine drug and widely used immunosuppressant for conditions such as systemic lupus erythematosus and inflammatory bowel disease. However, azathioprine has a narrow therapeutic index and thus may be discontinued due to adverse effects, primarily hematopoietic toxicity. The ACKR1 gene variant (the CC genotype) is found in approximately half of the individuals living in the United States with African ancestries. Further, this variant has been proposed to confer a higher rate of hematopoietic toxicity associated with discontinued use of azathioprine. However, there is a gap in knowledge as to understanding whether the CC genotype is associated with differences in thiopurine discontinuation and hematopoietic toxicity, particularly stratified by race, and age as well as TMPT and NUDT15 metabolizer status. This study found that patients with the CC genotype have a higher risk for azathioprine discontinuation attributed to hematopoietic toxicity and received lower doses of thiopurines, even after adjustment for race. This study was limited by data being restricted to tertiary centers, potentially resulting in preselection for access to care and/or socioeconomic factors. Nevertheless, these findings are significant, as they demonstrate that patients with the CC genotype are more likely to discontinue the use of azathioprine primarily due to hematopoietic toxicity.

Click to read the study in AIM

Relevant Reading: Beyond Race: A Wake-up Call for Drug Therapy Informed by Genotyping

In-Depth [retrospective cohort study]: This retrospective cohort study was conducted at a clinical practice-based biobank at Vanderbilt University Medical center, including 1,466 patients. Patients who were new azathioprine users, were prescribed azathioprine for inflammatory conditions, and had reported Black or White race were eligible for the study. Patients who had documented previous treatment with a thiopurine and previous medical history that could indicate compromised genetic material, such as a history of stem cell transplant, were excluded from the study. The primary outcome was discontinuation of azathioprine attributed to hematopoietic toxicity, defined as leukopenia, neutropenia, thrombocytopenia, pancytopenia, and/or anemia. Outcomes in the primary analysis were assessed via sensitivity analysis and estimation of incidence rates of azathioprine discontinuation attributed to hematopoietic toxicity. Based on the primary analysis, the rate of azathioprine discontinuation attributed to hematopoietic toxicity was 3.92 per 100 person-years in the CC-genotype patient group and 1.34 per 100 person-years in the TT or TC genotype (comparison group), resulting in a hazard ratio (HR) of 2.92 (95% Confidence Interval [CI], 1.57 to 5.41). The risk remained significant after race adjustment (HR 2.61, 95% CI 1.01 to 6.71). Lower last leukocyte count and lower dosing were also significant among the CC genotype patient group. The CC genotype was also independently associated with a lower 6-MP dose intensity relative to the target daily dose of 75 mg/m^2. Overall, this study demonstrates that patients with the CC genotype have a significantly higher risk of discontinuing azathioprine due to hematopoietic toxicity and lower overall thiopurine dose, which is independent of race.

RELATED REPORTS

Supplemental vitamin D does not reduce risk of fractures in older adults

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: ACKR1 variantazathioprineCC genotypechronic diseasegeneticshematologyhematopoietic toxicityimmunologyimmunosuppressantinflammatory bowel diseaseinflammatory conditionsrheumatologysystemic lupus erythematosus
Previous Post

#VisualAbstract: Molnupiravir improves outcomes in non-hospitalized COVID-19 patients

Next Post

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

RelatedReports

Proton pump inhibitor use in pediatric patients may increase fracture risk
Chronic Disease

Supplemental vitamin D does not reduce risk of fractures in older adults

August 5, 2022
2 Minute Medicine Rewind January 28, 2019
Chronic Disease

Methotrexate reduces functional burden of disease in patients with arthralgia at-risk of developing rheumatoid arthritis

August 3, 2022
Screening insufficient for newborns exposed to hepatitis C virus
Chronic Disease

Uptake of hepatitis C treatment in people who inject drugs associated with decreased liver disease

July 26, 2022
Separate panels of microRNAs may aid in early detection of pancreatic cancer
Chronic Disease

Low-dose AAVS3 gene therapy is efficacious for treating patients with hemophilia B

July 25, 2022
Next Post
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

Novel coronavirus identified from patients with pneumonia in Wuhan, China

Age-based products and longer interdose intervals may reduce the risk of cardiac disease following COVID-19 mRNA vaccination

Relugolix combination therapy is efficacious for endometriosis-associated pain

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Atherosclerotic risk factors associated with stroke in adulthood present from childhood and increase with age
  • CT-guided percutaneous lung biopsies more effective for larger pulmonary nodules [Classics Series]
  • Supplemental vitamin D does not reduce risk of fractures in older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.